Prepare for your visit

Venkata Reddivari

Nephrology (Internal Medicine) · Tampa, FL · NPI 1861685844

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$6,635.80

in general payments reported to CMS, 2019-2025 · $992 in 2025

The $992 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).

Who reported paying

General payments only, top 6 by amount.

Otsuka America Pharmaceutical, INC. $932.95
Opko Pharmaceuticals, LLC $707.10
Astrazeneca Pharmaceuticals LP $657.86
Bayer Healthcare Pharmaceuticals INC. $480.19
Calliditas Therapeutics US INC. $415.56
Amgen INC. $399.17

Drugs and devices associated with these payments

Tarpeyo Jynarque Farxiga Kerendia Ibsrela Jardiance Rayaldee Benlysta Lokelma Parsabiv Vafseo Lupkynis

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Venkata Reddivari listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1099837/venkata-reddivari